Pharminent

CAR-T Candidate Yields High Response Rates in Leukemia Study

A highly innovative, personalized cell-based treatment for a high-risk form of the most common childhood cancer continues to move through clinical trials.Contributed Author: The Children’s Hospital of PhiladelphiaTopics: Drug Pipeline http://www.dddmag.com/news/2016/12/car-t-candidate-yields-high-response-rates-leukemia-study

Filed under: Cancer, Immunotherapy